← 產業報告目錄
Psychedelic Therapeutics Market Size, Share & Trends Analysis Report, by Origin of Substance (Natural and Synthetic), Type of Psychedelic Substance (Gamma-hydroxybutyrate, Ketamine, MDMA, and Psilocybin), Target Disease Indications (Depression and Anxiety Disorders, Pain Disorders, Sleep Related Disorders and Trauma), Route of Administration, By Region, Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-19頁數 190報告編號 INSIGHTACE-e730dc6a65
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
With a 2024 valuation of USD 2.2 Billion, the global Psychedelic Therapeutics Market is projected to increase to USD 9.6 Billion by 2034, demonstrating a CAGR of 15.6% during the 2025–2034 forecast window.
Psychedelic Therapeutics encompasses also referred to as hallucinogenic. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is bolstered by a convergence of factors: rising awareness among end users, continuous product innovation, and the rising emphasis on efficiency and sustainability within the healthcare sector.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold marked shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and rising investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Psychedelic Therapeutics Market Snapshot
Chapter 4. Global Psychedelic Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Origin of Substance Estimates & Trend Analysis
5.1. by Origin of Substance & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Origin of Substance:
5.2.1. Natural
5.2.2. Synthetic
Chapter 6. Market Segmentation 2: by Type of Psychedelic Substance Estimates & Trend Analysis
6.1. by Type of Psychedelic Substance & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Psychedelic Substance:
6.2.1. Gamma-hydroxybutyrate
6.2.2. Ketamine
6.2.3. MDMA
6.2.4. Psilocybin
Chapter 7. Market Segmentation 3: by Target Disease Indications Estimates & Trend Analysis
7.1. by Target Disease Indications & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Target Disease Indications:
7.2.1. Depression and Anxiety Disorders
7.2.2. Pain Disorders
7.2.3. Sleep Related Disorders
7.2.4. Trauma
Chapter 8. Market Segmentation 4: by Route of Administration Estimates & Trend Analysis
8.1. by Route of Administration& Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Route of Administration:
8.2.1. Oral
8.2.2. Intravenous
8.2.3. Intranasal
8.2.4. Sublingual
Chapter 9. Psychedelic Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.1.2. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.1.3. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.1.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.1.5. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.2.2. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.2.3. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.2.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.2.5. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.3.2. Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.3.3. Asia-Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.3.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.3.5. Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.4. Latin America
9.4.1. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.4.2. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.4.3. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034 North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.4.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.4.5. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.5.2. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.5.3. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.5.4. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.5.5. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Celon Pharma S.A.
9.2.2. MAPS Public Benefit
9.2.3. MindMed
9.2.4. Janssen Pharmaceuticals
9.2.5. iX Biopharma Ltd
9.2.6. Jazz Pharmaceutical
9.2.7. Avadel
9.2.8. Pharmaceuticals plc
9.2.9. NeuroRx, Inc.
9.2.10. Douglas Pharmaceuticals Limited
9.2.11. The Emmes
9.2.12. Company, LLC
9.2.13. CaaMTech
9.2.14. COMPASS Pathways plc
9.2.15. Eleusis Benefit Corporation
9.2.16. AWAKN Life Sciences Inc
9.2.17. Psilera Bioscience
9.2.18. Braxia Scientific Corp.
9.2.19. Mindset Pharma
9.2.20. BetterLife Pharma
9.2.21. Cybin
9.2.22. CB Therapeutics
9.2.23. Numinus Wellness
9.2.24. Mydecine Innovations Group
9.2.25. Optimi Health
9.2.26. PharmaTher
9.2.27. Field Trip Health
9.2.28. ATAI Life Sciences
9.2.29. GH Research
9.2.30. Seelos Therapeutics
9.2.31. Small Pharma
9.2.32. Bright Minds Biosciences
9.2.33. Incannex Health
9.2.34. PsyBio Therapeutics
9.2.35. Universal Ibogaine
9.2.36. Levitee Labs
9.2.37. Mind Cure Health
9.2.38. Novamind
9.2.39. Clearmind Medicine
9.2.40. MYND Life Science
9.2.41. Wesana Health
9.2.42. Psyched Wellness
9.2.43. HAVN Life Sciences
9.2.44. Tryp Therapeutics
9.2.45. Psyence Group
9.2.46. Silo Pharma
9.2.47. Core One Labs
9.2.48. M2Bio Sciences
9.2.49. Neonmind Biosciences
9.2.50. Delic Corp
9.2.51. Nova Mentis Life Science
9.2.52. Beckley Psytech
9.2.53. Delix Therapeutics
9.2.54. Diamond Therapeutics
9.2.55. Tactogen
9.2.56. Psygen Labs Inc.
9.2.57. Bexson Biomedical
9.2.58. Eleusis Biotech
9.2.59. Psilera Biosceince
9.2.60. Octarine Bio
9.2.61. Heading Health
9.2.62. MAPS Public Benefit Corporation (PBC)
9.2.63. Aphrodite Health
9.2.64. Terran Biosciences
9.2.65. Mycrodose Therapeutics
9.2.66. Reset Pharma
9.2.67. Clerkenwell Health
9.2.68. Alvarius Pharmaceuticals
9.2.69. Ceruvia Lifesciences
9.2.70. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們